Blocking glutamate‐mediated signalling inhibits human melanoma growth and migration

Glutamate is an excitatory neurotransmitter that has been shown to regulate the proliferation, migration and survival of neuronal progenitors in the central nervous system through its action on metabotropic and ionotropic glutamate receptors (GluRs). Antagonists of ionotropic GluRs have been shown to cause a rapid and reversible change in melanocyte dendritic morphology, which is associated with the disorganization of actin and tubulin microfilaments in the cytoskeleton. Intracellular expression of microtubule‐associated protein (MAP) 2a affects the assembly, stabilization and bundling of microtubules in melanoma cells; stimulates the development of dendrites; and suppresses melanoma cell migration and invasion. In this study, we investigated the relationship between glutamate‐mediated signalling and microtubules, cell dendritic morphology and melanoma cell motility. We found that metabotropic GluR1 and N‐methyl‐d‐aspartate receptor antagonists increased dendritic branching and inhibited the motility, migration and proliferation of melanoma cells. We also demonstrated that the invasion and motility of melanoma cells are significantly inhibited by the combination of increased expression of MAP2a and either metabotropic GluR1 or N‐methyl‐d‐aspartate receptor antagonists. Moreover, the blockade of glutamate receptors inhibited melanoma growth in vivo. Collectively, these results demonstrate the importance of glutamate signalling in human melanoma and suggest that the blockade of glutamate receptors is a promising novel therapy for treating melanoma.

[1]  K. Roche,et al.  Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice , 2011, Proceedings of the National Academy of Sciences.

[2]  H. Lee,et al.  Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies , 2011, Clinical Cancer Research.

[3]  B. Wall,et al.  Riluzole Enhances Ionizing Radiation–Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo , 2011, Clinical Cancer Research.

[4]  P. Lu,et al.  Increased expression of MAP2 inhibits melanoma cell proliferation, invasion and tumor growth in vitro and in vivo , 2010, Experimental dermatology.

[5]  V. Memoli,et al.  Breast cancer expresses functional NMDA receptors , 2010, Breast Cancer Research and Treatment.

[6]  B. Wall,et al.  AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1) , 2010, Pigment cell & melanoma research.

[7]  C. Abels,et al.  Keratinocytes: a source of the transmitter l‐glutamate in the epidermis , 2009, Experimental dermatology.

[8]  C. Porta.  Mechanism of drug sensitivity and resistance in melanoma. , 2009 .

[9]  M. Kohno,et al.  Blockade of constitutively activated ERK signaling enhances cytotoxicity of microtubule-destabilizing agents in tumor cells. , 2009, Biochemical and biophysical research communications.

[10]  Shyun-Yeu Liu,et al.  Involvement of microtubule-associated protein 2 (MAP2) in oral cancer cell motility: a novel biological function of MAP2 in non-neuronal cells. , 2008, Biochemical and biophysical research communications.

[11]  W. Rzeski,et al.  AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth , 2007, Cancer biology & therapy.

[12]  M. Robinson,et al.  The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention , 2007, Neurochemistry International.

[13]  F. Nicoletti,et al.  Metabotropic glutamate receptors: new targets for the control of tumor growth? , 2007, Trends in pharmacological sciences.

[14]  N. Masuyama,et al.  The PI3K‐Akt pathway promotes microtubule stabilization in migrating fibroblasts , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[15]  Jin Namkoong,et al.  Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. , 2007, Cancer research.

[16]  C. Shashikant,et al.  Transcriptional regulation of human MAP2 gene in melanoma: role of neuronal bHLH factors and Notch1 signaling , 2006, Nucleic acids research.

[17]  Suzie Chen,et al.  Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon. , 2006, Cellular signalling.

[18]  P. Genever,et al.  Glutamate receptors on human melanocytes regulate the expression of MiTF. , 2006, Pigment cell research.

[19]  W. Rzeski,et al.  NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Segall,et al.  The great escape: when cancer cells hijack the genes for chemotaxis and motility. , 2005, Annual review of cell and developmental biology.

[21]  Zhen Yan,et al.  Microtubule Regulation of N-Methyl-D-aspartate Receptor Channels in Neurons* , 2005, Journal of Biological Chemistry.

[22]  F. Camacho,et al.  Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. , 2005, The American journal of pathology.

[23]  Suzie Chen,et al.  Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development , 2004, Journal of Molecular Medicine.

[24]  J. Wohlrab,et al.  N‐methyl‐D‐aspartate receptors influence the intracellular calcium concentration of keratinocytes , 2004, Experimental dermatology.

[25]  Wen‐yuan Zhu,et al.  Morphology of cultured human epidermal melanocytes observed by atomic force microscopy. , 2004, Pigment cell research.

[26]  P. Meltzer,et al.  Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia , 2003, Nature Genetics.

[27]  J. Silverman,et al.  Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. , 2003, Advances in anatomic pathology.

[28]  W. White,et al.  Expression of microtubule-associated protein 2 in benign and malignant melanocytes: implications for differentiation and progression of cutaneous melanoma. , 2001, The American journal of pathology.

[29]  W. Rzeski,et al.  Glutamate antagonists limit tumor growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Hinz,et al.  Actin-dependent lamellipodia formation and microtubule-dependent tail retraction control-directed cell migration. , 2000, Molecular biology of the cell.

[31]  P. Genever,et al.  Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. , 1999, The Journal of investigative dermatology.

[32]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[33]  L. Suva,et al.  Expression of an N-methyl-D-aspartate-type receptor by human and rat osteoblasts and osteoclasts suggests a novel glutamate signaling pathway in bone. , 1998, Bone.

[34]  E. Quinlan,et al.  Postsynaptic Mechanisms for Bidirectional Control of MAP2 Phosphorylation by Glutamate Receptors , 1996, Neuron.

[35]  K. Kosik,et al.  Suppression of MAP2 in cultured cerebeller macroneurons inhibits minor neurite formation , 1992, Neuron.

[36]  M. Cleary,et al.  Presence of functional NMDA receptors in a human neuroblastoma cell line. , 1997, Molecular and chemical neuropathology.

[37]  C. Cotman,et al.  The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. , 1989, Annual review of pharmacology and toxicology.